Anacor Announces U.S. Launch Of KERYDIN Topical Solution, 5%

(RTTNews) - Anacor Pharmaceuticals, Inc. (ANAC) on Monday announced the U.S. launch of its FDA-approved drug KERYDINTM topical solution, 5% by Sandoz Inc., a Novartis AG (NVS) company.

KERYDIN is the first oxaborole antifungal indicated for the topical treatment of onychomycosis of the toenails, a fungal infection of the nail and nail bed that affects about 35 million people in the United States, according to Podiatry Today.

Anacor said in July that it had entered into an exclusive agreement with Sandoz, pursuant to which Sandoz will distribute and commercialize KERYDIN in the United States.